We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+18.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.32B
AUM Growth
+$20.1M
Cap. Flow
+$138M
Cap. Flow %
10.43%
Top 10 Hldgs %
45.62%
Holding
85
New
8
Increased
16
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.7M
2
ALT icon
Altimmune
ALT
+$18.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$17.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$54M
2
IGMS
IGM Biosciences
IGMS
+$10.8M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.98M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.68M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
26
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$15.8M 1.2%
125,000
-25,000
-17% -$2.87M
CYTK icon
27
Cytokinetics
CYTK
$10.7B
$15.7M 1.19%
400,000
– –
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.7M 1.19%
275,000
+125,000
+83% +$7.09M
VECT
29
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$15.3M 1.16%
2,840,389
+761,904
+37% +$4.1M
GRNA
30
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$15.2M 1.15%
6,960,540
+250,000
+4% +$1.73M
STOK icon
31
Stoke Therapeutics
STOK
$1.99B
$14.4M 1.09%
1,087,807
– –
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$14.3M 1.08%
2,927,273
+437,379
+18% +$2.8M
BBIO icon
33
BridgeBio Pharma
BBIO
$16.1B
$13.3M 1.01%
1,469,179
-99,730
-6% -$834K
RAIN
34
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$12.9M 0.98%
2,326,660
– –
IMRX icon
35
Immuneering
IMRX
$284M
$12.4M 0.94%
2,286,181
-16,445
-0.7% -$87.7K
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$382M
$12M 0.9%
868,550
– –
SWTX
37
DELISTED
SpringWorks Therapeutics
SWTX
$11.7M 0.88%
+475,000
New +$17.4M
AVIR icon
38
Atea Pharmaceuticals
AVIR
$380M
$11M 0.83%
1,547,181
– –
VERV
39
DELISTED
Verve Therapeutics
VERV
$10.7M 0.81%
700,710
– –
VRDN icon
40
Viridian Therapeutics
VRDN
$2.33B
$10.2M 0.77%
877,500
-122,500
-12% -$1.65M
KZR
41
DELISTED
Kezar Life Sciences
KZR
$9.92M 0.75%
+120,000
New +$10.6M
VTYX
42
DELISTED
Ventyx Biosciences
VTYX
$9.55M 0.72%
780,643
-4,660
-0.6% -$69.6K
OLMA icon
43
Olema Pharmaceuticals
OLMA
$1.01B
$8.47M 0.64%
2,082,000
– –
AXSM icon
44
Axsome Therapeutics
AXSM
$11B
$7.85M 0.59%
+205,000
New +$6.48M
LBPH
45
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$7.02M 0.53%
2,273,221
– –
COGT icon
46
Cogent Biosciences
COGT
$7.22B
$6.76M 0.51%
+750,000
New +$5.12M
AMAM
47
DELISTED
Ambrx Biopharma Inc
AMAM
$6.59M 0.5%
2,486,386
– –
GHRS icon
48
GH Research
GHRS
$2B
$6.07M 0.46%
608,123
– –
BCAB icon
49
BioAtla
BCAB
$5.53M
$5.81M 0.44%
40,764
– –
ALXO icon
50
ALX Oncology
ALXO
$258M
$5.76M 0.44%
712,079
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Cormorant Asset Management held 85 positions worth $1.32B, up 1.5% from $1.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $138M of net new capital in Q2 2022, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Arcellx: 1,525,000 shares worth $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Turning Point Therapeutics, Inc. Common Stock, an estimated $54M trimmed.

  • Cormorant Asset Management's largest Q2 2022 buy was Arcellx: 1,525,000 shares worth $27.6M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2022, an estimated $17.5M increase.
  • Cormorant Asset Management's biggest Q2 2022 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $54M.
  • Cormorant Asset Management fully exited IGM Biosciences in Q2 2022, selling an estimated $10.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.32B portfolio in Q2 2022.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q2 2022.
  • Cormorant Asset Management's portfolio value rose 1.5% quarter-over-quarter to $1.32B.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.